REG - Beximco Pharmaceut - AGM Statement

Beximco PharmaceuticalsAnnouncement

21/12/2020 07:00

RNS Number : 2632J
  
Beximco Pharmaceuticals Ltd
  
21 December 2020
  
 

21 December 2020
 
BEXIMCO PHARMACEUTICALS LIMITED
 
Annual General Meeting Statement
 
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that all resolutions put before shareholders at the Company's Annual General Meeting ("AGM") held virtually on 19 December 2020 were duly passed.:
 
The resolutions passed at the AGM included the approval of 15% cash dividend and 10% stock dividend for the year ended on 30 June 2020. The cash dividend being 15% of the nominal value per ordinary share of Taka 10 (Taka 1.5 per ordinary share/per global depository receipt ("GDR") held in respect of GDR holders) will be paid to holders of ordinary shares/GDRs (who were on the register of shareholders'/GDR holders' as on the date of record, i.e. 25 November 2020) on 17 January 2021. The cash dividend will be paid after deduction of taxes as per Bangladesh Tax law.
 
It is intended that the new ordinary shares/GDRs arising from the 10% stock dividend i.e. 10 ordinary shares/GDRs per 100 ordinary shares/GDRs (in respect of GDR holders) held, will be credited to shareholders/GDR holders accounts on or before 17 January 2021.
 
Application will be made for admission of the new GDRs arising from the stock dividend ("New GDRs") to be admitted to trading on AIM ("Admission"). Admission is expected to take place shortly after the New GDRs are credited to the respective accounts and a further announcement will be made in due course with the expected date of Admission.
 
Following issuance of the stock dividend, the total issued share capital of the Company will be 446,112,089 ordinary shares of Taka 10 ("Ordinary Shares"), of which 100,037,989 will be represented by GDRs. The new Ordinary Shares will rank pari passu in all respects with the existing issued Ordinary Shares, all having voting rights.
 
The Annual Report for 2019-20 is available from the Company's website, which includes the audited accounts and a review of operations for the year ended on 30 June 2020.
 
For further information please visit www.beximcopharma.com or enquire to: 
 



Beximco Pharma




Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, Ext. 20080
 




Mohammed Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext. 20030
 
Mohammad Asad Ullah, FCS, Executive Director & Company Secretary
Tel: +880 2 58611891, +880 2 58612040, Ext. 10140
 




SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
 




SP Angel Corporate Finance LLP (Broker)
Vadim Alexandre / Abigail Wayne
Tel: +44 (0) 20 3470 0470
 




FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
 



 
Notes to Editors
 
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
 
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 4,700 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
AGMURSORRUUUUUA